Abstract
The major criticisms made to the conceptualization of PMDD as a clinical syndrome focus on pathologizing of women’s biology and its consequent medicalization which perpetuated misconceptions related to menses. This is a reality in History of Medicine. The excessive medicalization of the menstrual experience that interferes in life is very important in Western countries. Premenstrual syndrome (PMS) is a health problem that affects millions of women of reproductive age and, in some cases, may be severe enough to be considered as a premenstrual dysphoric disorder (PMDD). Both, PMS and PMDD, are composed by affective, behavioural, and physical symptoms. Risk factors identified, which predispose to PMS/PMDD, are the age between 25 and 35 years, to have a psychiatric history, family history of PMDD, unhealthy living habits, and the apparition of stressful life events. In addition to that, it has been established a comorbidity of PMDD with various psychiatric disorders as major depression and anxiety disorders. The first-line treatment for PMDD is pharmacological with SSRIs. From the medical point of view, there is some evidence of the efficacy of non-pharmacological treatments such as relaxation and aerobic and cognitive behavioural therapy that are used mostly in mild cases. Some authors remind us the historical and negative conceptions about the female body plus a reproductivist vision, as the cause of many women’s behaviour, have had a determinate influence in the consideration about women’s experience as diseases. In our opinion, we consider it is important to rethink about it and talk about premenstrual experience instead of syndrome. It could be used to reinforce and maintain the patriarchal model. If women are treated medically because of their own biology, they would respond again to the female stereotype of women as mild, placid, and undemanding. At the same time, for some women could represent an attractive explanation to justify their oppression and their relative lack of success compared to men. This means that women can attribute their subordination and oppression to something identifiable and potentially curable, rather than attributing to gender power relations. Finally, the concept clearly benefits to the pharmaceutical industry, as the medicalization of premenstrual experiences increased their market.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schechter D. Estrogen, progesterone, and mood. J Gend Specif Med. 1999;2(1):29–36.
Gurevich M. Rethinking the label: who benefits from the PMS construct? Women Health. 1995;23(2):67–98.
Jensvold MF, Dan CE. Psychological aspects of women’s health care: the interface between psychiatry and obstetrics and gynaecology. Washington, DC: American Psychiatric Publishing; 2001.
Richardson J. The premenstrual syndrome: a brief history. Soc Sci Med. 1995;6(41):761–7.
Dalton K. El Síndrome Premenstrual. Proteo: México; 1967.
García Porta M. Síndrome premenstrual: Aproximación crítica. AIBR Revista de Antropología Iberoamericana [Internet]. 2006 [cited 2013 June 25]; 1(1):80–102. http://www.aibr.org/antropologia/01v01/articulos/010105.pdf.
Dennerstein L, Lehert P, Heinemann K. Epidemiology of premenstrual symptoms and disorders. Menopause Int. 2012;18(2):48–51.
Sattar K. Epidemiology of premenstrual syndrome, a systematic review and meta-analysis study. J Clin Diag Res. 2014;8(2):106–9.
O’Brien PM, Bäckström T, Brown C, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14:13–21.
Yonkers KA, O’Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008;371(9619):1200–10.
Freeman EW, Halberstadt SM, Rickels K, et al. Core symptoms that discriminate premenstrual syndrome. J Womens Health (Larchmt). 2011;20(1):29–35.
Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology. 2003;3:25–37.
Pilver CE, Libby DJ, Hoff RA. Premenstrual dysphoric disorder as a correlate of suicidal ideation, plans, and attempts among a nationally representative sample. Soc Psychiatry Psychiatr Epidemiol. 2013;48(3):437–46.
Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res. 2009;9(2):157–70.
Cohen LS, Soares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord. 2002;70:125.
Freeman EW, Sammel MD, Rinaudo PJ, Sheng L. Premenstrual syndrome as a predictor of menopausal symptoms. Obstet Gynecol. 2004;103(5 Pt 1):960–6.
Di Giulio G, Reissing ED. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J Psychosom Obstet Gynaecol. 2006;27(4):201–10.
Andersch B, Abrahamsson L, Wendestam C, et al. Hormone profile in premenstrual tension: effects of bromocriptine and diuretics. Clin Endocrinol (Oxf). 1979;11:657.
Taylor JW. Plasma progesterone, oestradiol 17 beta and premenstrual symptoms. Acta Psychiatr Scand. 1979;60:76.
World Health Organization. Mental health: new understanding, new hope. Geneva: Halbreich; 2001.
Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomology on functioning and treatment-seeking behaviour: experience from the United States, United Kingdom and France. J Womens Health Gend Based Med. 1999;8:1043–52.
Kuan AJ, Carter DM, Ott FJ. Distress levels in patients with premenstrual dysphoric disorder. Can J Psychiatr. 2002;47:888–9.
Campbell EM, Peterkin D, O’Grady K, Sanson-Fisher R. Premenstrual symptoms in general practice patients: prevalence and treatment. J Reprod Med. 1997;42:637–46.
Hofmeister S, Bodden S. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2016;94(3):236–40.
Appleton SM. Premenstrual syndrome: evidence-based evaluation and treatment. Clin Obstet Gynecol. 2018;61(1):52–61.
Hengartner MP, Kruger TH, Geraedts K, Tronci E, Mancini T, Ille F, et al. Negative affect is unrelated to fluctuations in hormone levels across the menstrual cycle: evidence from a multisite observational study across two successive cycles. J Psychosom Res. 2017;99:21–7.
Ismail K, Robinson L. Clinical epidemiology of premenstrual disorder: informing optimized patient outcomes. Int J Women’s Health. 2015;7:811–8.
Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338(4):209–16.
Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med. 1998;129(3):229–40.
Wardlaw SL, Thoron L, Frantz AG. Effects of sex steroids on brain beta-endorphin. Brain Res. 1982;245(2):327.
Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986;232(4753):1004.
Bethea CL. Regulation of progestin receptors in raphe neurons of steroid-treated monkeys. Neuroendocrinology. 1994;60(1):50–61.
Chuong CJ, Coulam CB, Kao PC, Bergstralh EJ, Go VL. Neuropeptide levels in premenstrual syndrome. Fertil Steril. 1985;44(6):760–5.
Reid RL, Yen SS. Premenstrual syndrome. Am J Obstet Gynecol. 1981;139(1):85–104.
Cunningham J, Yonkers KA, O’Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17(2):120–37.
Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry. 1997;58(Suppl. 15):19–25.
Wirst-Justice et al. Citado en Jensvold MF. Nonpregnant reproductive age women. In: Psychopharmacology and women. Washington, DC: American Psychiatric Press; 1996. p. 139–69.
Roca CA, Schmidt PJ, Smith MJ, et al. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry. 2002;159(11):1876.
Steinberg S, Annable L, Young SN, Liyanage N. A placebo controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry. 1999;45(3):313–20.
Brzezinski AA, Wurtman JJ, Wurtman RJ, Gleason R, Greenfield J, Nader T. D-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves mood of women with premenstrual depression. Obstet Gynecol. 1990;76(2):296–301.
Scalea TLD, Pearlstein T. Premenstrual dysphoric disorder. Psychiatr Clin North Am. 2017;40(2):201–16.
Sherwood RA, Rocks BF, Stewart A, Saxton RS. Magnesium and the premenstrual syndrome. Ann Clin Biochem. 1986;23(Pt 6):667.
Facchinetti F, Borella P, Fioroni L, et al. Reduction of monocyte’s magnesium in patients affected by premenstrual syndrome. J Psychosom Obstet Gynaecol. 1990;11:221–9.
Bahrami A, Bahrami-Taghanaki H, Afkhamizadeh M, Avan A, Khorasani ZM, Esmaeili H, et al. Menstrual disorders and premenstrual symptoms in adolescents: prevalence and relationship to serum calcium and vitamin D concentrations. J Obstet Gynaecol. 2018;21:1–7.
Batra NA, Seres-Mailo J, Hanstock C, et al. Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder. Biol Psychiatry. 2008;63(12):1178–84.
Protopopescu X, Butler T, Pan H, et al. Hippocampal structural changes across the menstrual cycle. Hippocampus. 2008;18(10):985–8.
Liu P, Wei Y, Liao H, Fan Y, Li R, Feng N, et al. Thalamocortical dysconnectivity in premenstrual syndrome. Brain Imaging Behav. 2018. https://doi.org/10.1007/s11682-018-9894-0.
Liu P, Wei Y, Fan Y, Li R, Liu Y, Wang G, Wei Y, Pang Y, Deng D, Qin W. Altered brain structure in women with pre- menstrual syndrome. J Affect Disord. 2018;229:239–46.
Kondo M, Hirano T, Okamura Y. Changes in autonomic nerve function during the normal menstrual cycle measured by the coefficient of variation of R-R intervals. Nippon Sanka Fujinka Gakkai Zasshi. 1989;41(5):513–8.
Matsumoto T, Ushiroyama T, Morimura M, et al. Autonomic nervous system ativity in the late luteal phase of eumenorrheic women with premenstrual symptomatology. J Psychosom Obstet Gynaecol. 2006;27(3):131–9.
Baker FC, Kahan TL, Trinder J, Colrain IM. Sleep quality and the sleep electroencephalogram in women with severe premenstrual syndrome. Sleep. 2007;30(10):1283–91.
Chrisler JC, Johnston-Robledo I. Raging hormones? Feminist perspectives on premenstrual syndrome and postpartum depression. In: Ballou M, Brown LS, editors. Rethinking mental health and disorder: feminist perspectives. New York: Guilford Press; 2002. p. 174–97.
Sigmon ST, et al. The role of enxiety level, coping styles and cycle phase in menstrual distresws. J Anxiety Disord. 2004;18(2):177–91.
Blake F. Cognitive therapy for premenstrual syndrome. Cogn Behav Pract. 1995;2:167–85.
Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med. 1999;8(2):122–8.
Ramcharan S, Love EJ, Fick GH, Goldfien A. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol. 1995;45(4):377–92.
Wittchen H-U, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 2002;32(1):119–32.
Perarnau MP, et al. Síntomas, Síndrome y Trastorno Disfórico Premenstrual en una muestra de mujeres universitarias. Fundamentos en Humanidades. 2010;2(Pt11):195–209.
Bocchino S. Salud Mental de la Mujer. Boletín Sociedad de Psiquiatría del Uruguay. 2004;68(1):78–89.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders-IV-TR. Barcelona: Masson; 2002.
Perez-Lopez FR, et al. Premenstrual síndrome and premenstrual dysphoric disorder: symptoms and cluster influences. Open Psychiatry J. 2009;3:39–49.
Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry. 1993;162:481–6.
Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry. 1998;155(9):1234–40.
McEvoy K, Osborne LM, Nanavati J, Payne JL. Reproductive affective disorders: a review of the genetic evidence for premenstrual dysphoric disorder and postpartum depression. Curr Psychiatry Rep. 2017;19(12):94.
Krantz G, Ostergren PO. Common symptoms in middle aged women: their relation to employment status, psychosocial work conditions and social support in a Swedish setting. J Epidemiol Community Health. 2000;54(3):192–9.
Bertone-Johnson ER, Hankinson SE, et al. Cigarette smoking and the development of premenstrual syndrome. Am J Epidemiol. 2008;168(8):938–45.
Masho SW, Adera T, South-Paul J. Obesity as a risk factor for premenstrual syndrome. J Psychosom Obstet Gynaecol. 2005;26(1):33–9.
Bertone-Johnson ER, Hankinson SE, Willett WC, Johnson SR, Manson JE. Adiposity and the development of premenstrual syndrome. J Womens Health (Larchmt). 2010;19(11):1955–62.
Chocano-Bedoya PO. Intake of selected minerals and risk of premenstrual syndrome. Am J Epidemiol. 2013;177(10):1118–27.
Potter J, Bouyer J, et al. Premenstrual syndrome prevalence and fluctuation over time: results from a French population-based survey. J Womens Health (Larchmt). 2009;18(1):31–9.
Pilver CE, Kasl S, Desai R, Levy BR. Health advantage for black women: patterns in premenstrual dysphoric disorder. Psychol Med. 2011;41(8):1741–50.
Bertone-Johnson ER, Whitcomb BW, Missmer SA, Manson JE, Hankinson SE, Rich-Edwards JW. Early life emotional, physical, and sexual abuse and the development of premenstrual syndrome: a longitudinal study. J Womens Health (Larchmt). 2014;23(9):729–39.
Golding JM, Taylor DL, Menard L, King MJ. Prevalence of sexual abuse history in a sample of women seeking treatment for premenstrual syndrome. J Psychosom Obstet Gynecol. 2000;21:69–80.
Eisenlohr-Moul TA, Rubinow DR, Schiller CE, Johnson JL, Leserman J, Girdlera SS. Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder. Psychoneuroendocrinology. 2016;67:142–52.
Pilver CE, Levy BR, Libby DJ, Desai RA. Posttraumatic stress disorder and trauma characteristics are correlates of premenstrual dysphoric disorder. Arch Womens Ment Health. 2011;14(5):383–93.
Nillni YI, Berenz EC, Pineles SL, Coffey SF, Zvolensky MJ. Anxiety sensitivity as a moderator of the association between premenstrual symptoms and posttraumatic stress disorder symptom severity. Psychol Trauma. 2014;6(2):167–75.
ACOG. ACOG practice bulletin: premenstrual syndrome. Int J Gynecol Obstet. 2000;73:183–91.
Steege JF, Blumenthal JA. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res. 1993;37(2):127–33.
Aganoff JA, Boyle GJ. Aerobic exercise, mood states and menstrual cycle symptoms. J Psychosom Res. 1994;38:183.
Goodale IL, Domar AD, Benson H. Alleviation of premenstrual syndrome symptoms with the relaxation response. Obstet Gynecol. 1990;75:649.
Lustyk MKB, Widman L, Paschane A, Ecker E. Women Health. 2004a;39:35–44.
Lustyk MKB, Widman L, Paschane A, Olson KC. Behav Med. 2004b;30:124–31.
Daley A. Exercise and premenstrual symptomatology: a comprehensive review. J Womens Health (Larchmt). 2009;18:895–9.
Portella AT, Haaga DA, Rohan KJ. The association between seasonal and premenstrual symptoms is continuous and is not fully accounted for by depressive symptoms. J Nerv Ment Dis. 2006;194:833–7.
Sepede G, Sarchione F, Matarazzo I, Di Giannantonio M, Salerno RM. Premenstrual dysphoric disorder without comorbid psychiatric conditions: a systematic review of therapeutic options. Clin Neuropharmacol. 2016;39:241–61.
Reid RL, Soares CN. Premenstrual dysphoric disorder: contemporary diagnosis and management. J Obstet Gynaecol Can. 2018;40:215–23.
Stewart A. Vitamin B6 in the treatment of the premenstrual syndrome—review. Br J Obstet Gynaecol. 1991;98:329.
Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998;179:444.
Walker AF, De Souza MC, Vickers MF, et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Women’s Health. 1998;7:1157.
London RS, Murphy L, Kitlowski KE, Reynolds MA. Efficacy of alpha-tocopherol in the treatment of the premenstrual syndrome. J Reprod Med. 1987;32:400.
Parry BL, Berga SL, Mostofi N, Sependa PA, Kripke DF, Gillin JC. Morning versus evening bright light treatment of late luteal phase dysphoric disorder. Am J Psychiatry. 1989;146:1215–7.
Rossignol AM, Bonnlander H. Caffeine-containing beverages, total fluid consumption, and premenstrual syndrome. Am J Public Health. 1990;80:1106–10.
Wyatt KM, Dimmock PW, Jones PW, Shaughn O’Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999;318:1375.
Brown J, O’Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009;2:CD001396.
Shah NR, Jones JB, Aperi J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol. 2008;111:1175.
Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998;18:390.
Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993;9:133.
Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2002;100(6):1219–29.
Landen M, Nissbrandt H, Allgulander C, Sorvik K, Ysander C, Eriksson E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology. 2007;32:153–61.
Sundblad C, Wikander I, Andersch B, Eriksson E. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side effects during ten cycles of treatment. Eur Neuropsychopharmacol. 1997;7:201–6.
Yonkers K, Holthausen G, Poschman K, Howell H. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol. 2006;26:198–202.
Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992;85:39.
Freeman EW, Rickels K, Sondheimer SJ, et al. Nefazodone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol. 1994;14:180.
Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001;98:737.
Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol. 1987;70:37.
Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry. 1990;47:270.
Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contra- ceptive formulation. Contraception. 2005;72:414–21.
Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res. 1993;37:195–202.
Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res. 1992;36:257–66.
Sulak P, Scow R, Preece C, Riggs M, Kuehl T. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–6.
Sulak P, Kuehl T, Ortiz M, Schull B. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–9.
Freeman EW. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Eur J Contracept Reprod Health Care. 2002;7(Suppl. 3):27–34.
Lopez L, Kaptein A, Helmerhorst F. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2008;1:CD006586.
Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Exp Opin Pharmacother. 2007;8:989–99.
Yonkers K, Brown C, Pearlstein T, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501.
Rodin M. The social construction of premenstrual syndrome. Soc Sci Med. 1992;35(1):49–56.
Figert AE. Premenstrual syndrome as scientific and cultural artifact. Integr Physiol Behav Sci. 2005;40(2):102–13.
Chrisler JC, Caplan P. The strange case of Dr. Jekyll and Ms. Hyde: how PMS became a cultural phenomenon and a psychiatric disorder. Annu Rev Sex Res. 2002;13:274–306.
Zachar P, Kendler KS. A diagnostic and statistical manual of mental disorders history of premenstrual dysphoric disorder. J Nerv Ment Dis. 2014 Apr;202(4):346–52.
Johnson TM. Premenstrual syndrome as a western culture-specific disorder. Cult Med Psychiatry. 1987;11(3):337.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sáenz-Herrero, M., Sanchez-Palacios, A., Santamaria, M., Lago-Santos, I. (2019). Premenstrual Experience, Premenstrual Syndrome, and Dysphoric Disorder. In: Sáenz-Herrero, M. (eds) Psychopathology in Women. Springer, Cham. https://doi.org/10.1007/978-3-030-15179-9_20
Download citation
DOI: https://doi.org/10.1007/978-3-030-15179-9_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-15178-2
Online ISBN: 978-3-030-15179-9
eBook Packages: MedicineMedicine (R0)